A dual antitumor polypeptide based on the EPS8-EGFR binding domain

An eps8-egfr, anti-tumor technology, applied in the field of preparation of anti-tumor drugs, can solve the problems of unsatisfactory inhibition effect and low inhibition rate of tumor cell proliferation
CN105859865BInactive Publication Date: 2019-07-05SOUTHERN MEDICAL UNIVERSITY
4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN Ā· China
Patent Type
Patents(China)
Current Assignee / Owner
SOUTHERN MEDICAL UNIVERSITY
Publication Date
2019-07-05
Estimated Expiration
Not applicable Ā· inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a dual anti-tumor polypeptide based on the Eps8-EGFR binding domain. The amino acid sequence of the polypeptide is Glu-Phe-Leu-Asp-Cys-Phe-Gln-Lys-Phe (SEQ ID No:1). The dual anti-tumor polypeptide can induce toxic T cells, effectively kills HLA-A*2402 positive tumors and Eps8 positive tumors, can directly inhibit proliferation of HLA-A*2402 positive tumor cells and Eps8 positive tumor cells, and can be used for preparing dual anti-tumor medicine.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of organic chemistry, in particular to a polypeptide from mammals, which has anti-tumor activity and is suitable for preparing anti-tumor drugs. Background technique

[0002] Peptide drugs have very important development value in clinical application. Some peptide drugs have the effect of promoting the immune function of the body, which are called peptide vaccines. The identification of novel tumor antigens that induce strong and specific antitumor immune responses warrants the development and clinical application of peptide vaccines against various types of tumors (Reche P, et al. J Immunol Res2015; 2015:349049; Jazirehi AR, et al .Cancer Res 2011; 71(4):1406-1417; Andersen RS, et al. Cancer Immunol Immunother 2011; 60(2):227-234; Gritzapis AD, et al. Cancer Res 2010; 70(7):2686-2696 ; Klepin HD, et al. Oncologist 2009; 14(3):222-232.). So far, there have been many clinical trials using tumor-associated antigen-de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More